Literature DB >> 33946927

Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation.

Chelsea Schiliro1, Bonnie L Firestein2.   

Abstract

Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth and proliferation. These metabolic alterations include (1) a shift from oxidative phosphorylation to aerobic glycolysis to support the increased need for ATP, (2) increased glutaminolysis for NADPH regeneration, (3) altered flux through the pentose phosphate pathway and the tricarboxylic acid cycle for macromolecule generation, (4) increased lipid uptake, lipogenesis, and cholesterol synthesis, (5) upregulation of one-carbon metabolism for the production of ATP, NADH/NADPH, nucleotides, and glutathione, (6) altered amino acid metabolism, (7) metabolism-based regulation of apoptosis, and (8) the utilization of alternative substrates, such as lactate and acetate. Altered metabolic flux in cancer is controlled by tumor-host cell interactions, key oncogenes, tumor suppressors, and other regulatory molecules, including non-coding RNAs. Changes to metabolic pathways in cancer are dynamic, exhibit plasticity, and are often dependent on the type of tumor and the tumor microenvironment, leading in a shift of thought from the Warburg Effect and the "reverse Warburg Effect" to metabolic plasticity. Understanding the complex nature of altered flux through these multiple pathways in cancer cells can support the development of new therapies.

Entities:  

Keywords:  Warburg Effect; aerobic glycolysis; cancer; one-carbon metabolism; oxidative phosphorylation; pentose phosphate pathway

Year:  2021        PMID: 33946927     DOI: 10.3390/cells10051056

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  277 in total

1.  Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.

Authors:  Mark Stein; Hongxia Lin; Chandrika Jeyamohan; Dmitri Dvorzhinski; Murugesan Gounder; Kevin Bray; Simantini Eddy; Susan Goodin; Eileen White; Robert S Dipaola
Journal:  Prostate       Date:  2010-09-15       Impact factor: 4.104

Review 2.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

3.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Adrian L Harris; Efthimios Sivridis
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

4.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

5.  A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation.

Authors:  Arpit Dheeraj; Chapla Agarwal; Isabel R Schlaepfer; David Raben; Rana Singh; Rajesh Agarwal; Gagan Deep
Journal:  Hypoxia (Auckl)       Date:  2018-08-21

Review 6.  The Diverse Functions of Non-Essential Amino Acids in Cancer.

Authors:  Bo-Hyun Choi; Jonathan L Coloff
Journal:  Cancers (Basel)       Date:  2019-05-15       Impact factor: 6.639

7.  Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.

Authors:  Huai-Qiang Ju; Yun-Xin Lu; Dong-Liang Chen; Zhi-Xiang Zuo; Ze-Xian Liu; Qi-Nian Wu; Hai-Yu Mo; Zi-Xian Wang; De-Shen Wang; Heng-Ying Pu; Zhao-Lei Zeng; Bo Li; Dan Xie; Peng Huang; Mien-Chie Hung; Paul J Chiao; Rui-Hua Xu
Journal:  J Natl Cancer Inst       Date:  2019-06-01       Impact factor: 13.506

8.  The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling.

Authors:  Alex Shimura Yamashita; Marina da Costa Rosa; Vittorio Stumpo; Rana Rais; Barbara S Slusher; Gregory J Riggins
Journal:  Neurooncol Adv       Date:  2020-10-29

9.  Serine, glycine and one‑carbon metabolism in cancer (Review).

Authors:  Sijing Pan; Ming Fan; Zhangnan Liu; Xia Li; Huijuan Wang
Journal:  Int J Oncol       Date:  2020-12-11       Impact factor: 5.650

10.  Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.

Authors:  Oliver D K Maddocks; Celia R Berkers; Susan M Mason; Liang Zheng; Karen Blyth; Eyal Gottlieb; Karen H Vousden
Journal:  Nature       Date:  2012-12-16       Impact factor: 49.962

View more
  25 in total

Review 1.  Metabolic changes during prostate cancer development and progression.

Authors:  Alicia-Marie K Beier; Martin Puhr; Matthias B Stope; Christian Thomas; Holger H H Erb
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-23       Impact factor: 4.322

2.  MALDI Mass Spectrometry Imaging Highlights Specific Metabolome and Lipidome Profiles in Salivary Gland Tumor Tissues.

Authors:  Eduardo Sommella; Emanuela Salviati; Vicky Caponigro; Manuela Grimaldi; Simona Musella; Alessia Bertamino; Luigi Cacace; Remo Palladino; Giuseppe Di Mauro; Federico Marini; Anna Maria D'Ursi; Pietro Campiglia
Journal:  Metabolites       Date:  2022-06-08

3.  Assessment of Serum Urea, Creatinine and Uric Acid in Oral Cancer.

Authors:  Ana Caruntu; Liliana Moraru; Diana Alina Ciubotaru; Cristiana Tanase; Cristian Scheau; Constantin Caruntu
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 4.  Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.

Authors:  Beatrice Aramini; Valentina Masciale; Giulia Grisendi; Federica Bertolini; Michela Maur; Giorgia Guaitoli; Isca Chrystel; Uliano Morandi; Franco Stella; Massimo Dominici; Khawaja Husnain Haider
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

5.  A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity.

Authors:  Yawei Li; Qing Pei; Baiji Cui; Hongmei Zhang; Liu Han; Wenqing Li; Wenhe Zhu; Xianmin Feng; Zhigang Xie
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

6.  Metabolic Reprogramming in Response to Alterations of Mitochondrial DNA and Mitochondrial Dysfunction in Gastric Adenocarcinoma.

Authors:  Tzu-Ching Chang; Hui-Ting Lee; Siao-Cian Pan; Shih-Han Cho; Chieh Cheng; Liang-Hung Ou; Chia-I Lin; Chen-Sung Lin; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

Review 7.  Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease.

Authors:  Antonio Enrico Zaurito; Markus Tschurtschenthaler
Journal:  Metabolites       Date:  2022-01-07

8.  Glucose starvation suppresses gastric cancer through targeting miR-216a-5p/Farnesyl-Diphosphate Farnesyltransferase 1 axis.

Authors:  Ruiyang Zhao; Bo Cao; Hanghang Li; Tian Li; Xingming Xu; Hao Cui; Huan Deng; Bo Wei
Journal:  Cancer Cell Int       Date:  2021-12-25       Impact factor: 5.722

Review 9.  Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis.

Authors:  Hiroshi Kobayashi; Shogo Imanaka; Hiroshi Shigetomi
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

Review 10.  Hallmarks of Metabolic Reprogramming and Their Role in Viral Pathogenesis.

Authors:  Charles N S Allen; Sterling P Arjona; Maryline Santerre; Bassel E Sawaya
Journal:  Viruses       Date:  2022-03-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.